How to deliver new vaccines under very short timelines: The ZAPI project by AUDONNET, Jean-Christophe
Engineering Conferences International
ECI Digital Archives
Vaccine Technology VI Proceedings
6-16-2016
How to deliver new vaccines under very short
timelines: The ZAPI project
Jean-Christophe AUDONNET
DVM, Ph.D, Merial S.A.S., France, jean-christophe.audonnet@merial.com
Follow this and additional works at: http://dc.engconfintl.org/vaccine_vi
Part of the Engineering Commons
This Abstract and Presentation is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion
in Vaccine Technology VI by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.
Recommended Citation
Jean-Christophe AUDONNET, "How to deliver new vaccines under very short timelines: The ZAPI project" in "Vaccine Technology
VI", Laura Palomares, UNAM, Mexico Manon Cox, Protein Sciences Corporation, USA Tarit Mukhopadhyay, University College
London, UK Nathalie Garçon, BIOASTER Technology Research Institute, FR Eds, ECI Symposium Series, (2016).
http://dc.engconfintl.org/vaccine_vi/37
Zoonoses Anticipation and 
Preparedness Initiative 
Jean-Christophe Audonnet DVM, Ph.D. 
ZAPI IMI Project Coordinator 
How to deliver new vaccines 
under very short timelines ? 
Vaccine Technology Conference VI, Albufeira, June 16 , 2016  





• The ZAPI project is not focused on specific commercial 
products. 
 
• The ZAPI project aims to design new manufacturing 
large scale capability processes for neutralizing 
reagents and vaccines against zoonotic diseases. 
 
• These new R&D and manufacturing processes should 
be usable both for animal and human health needs 
 




The need to anticipate the future… 
and preparedness activities 
• It is always better to anticipate the risks.. 
 
• Major bio-threats are known (OIE list + (new 
arthropod-borne diseases) + WHO initiatives… 
 
• However, experience and recent history show 
that some events are unpredictable…. And we 
actually face the “unexpected” more and more. 
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Global needs for new vaccines 
• VACCINE PRODUCT « BY DESIGN »: 
 
– Selection of protective immunogens 
 
– Adjuvants, Immuno-modulators 
 
– Delivery systems 
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Global needs for new vaccines 
• TECHNOLOGIES 
– Many advantages to use recombinant  technologies 
as solutions for industrial bottlenecks: 
 
• No handling of pathogens 
 
• Large manufacturing capacity 
 
• Less biological variability for the final product 
 
• Easier QC testing for batch release 
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• Timelines (very short by definition = a few months…) 
 
• Manufacturing capacity (with secured supply chains for 
raw materials = source of many bottlenecks) 
 
• Reliable processes / fully in vitro QC tools 
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Technical constraints (2)…. 
 
• Contained ABSL-3, ABSL-3+, ABSL-4 animal facilities for 
testing vaccines … 
 
• Stockpiling storage: 
– Vaccine stability, facilities for vaccine storage  will drive the 
selection of technical solutions 
 
• If “immediate use” (implies efficient “surge capacity”): 
– No need for long term stability (and for stockpiling ?) 
Challenges for delivering 
emergency vaccines 
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Technical constraints (3)…. 
 
• Manufacturing capacities (with secured supply chains 
for raw materials) (“capacity” can be a very complex 
figure): 
– Minimum number of doses 
– Dose of antigen (linked to adjuvant, delivery route) 
– Key equipment for the process 
– Manufacturing average cycle time (reliability of process, 
batch release success rate…) 
– Stability (shelf life) 
Challenges for delivering 
emergency vaccines 
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“New thinking” as part of 
the preparedness  
• Need to work with an “Industrial mindset” rather 
than a “scientific mindset”. At the end of the day, 




• Better preparedness if vaccine solutions are based 
on the “re-use” of existing (proven) manufacturing 
technologies. 
11 
“New thinking” as part of 
the preparedness  
• Viruses are perceived today as technically 
achievable for this objective. 
 
• 3 viral models are used in the ZAPI project: 
– Rift  Valley Fever Virus 
– Schmallenberg Virus 
– MERS-CoV 
 
• Key progress in bioinformatics and new expression 
systems enable now the implementation of 
efficient subunit vaccine solutions 
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Conclusions (1) 
• For « expected events », the best approach is to 
stockpile  (« no delay » between identification and 
implementation of field vaccination) 
• However, this is associated with costs,  technical 
issues, and uncertainties… 
 
• For « unexpected events », all timelines become 
highly critical: 
 
• Identification of pathogen / immunogen is key 
 
• « Quality by Design » of the optimal vaccine for 
« instant » manufacturing capacities 
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Necessity to innovate for designing subunit vaccines fit to 
robust and « high yield » expression systems / 
processes: 
• Effectively achieving delivery of a product with 
existing GMP facilities 
• Ensuring surge manufacturing capacity 
 
Timelines are critical for well-adapted responses: 
 
• Select solutions enabling a short cycle time for 
production: 
• Rapid antigen production with high « volumetric 
yields » 
• Fast Quality Control (in vitro) for batch release 
Conclusions (2) 
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We are in a global « One World / One Health » 
 
• Anyone (domestic animals, people) can or will be 
exposed to new (re-)emerging diseases. 
• The « reduction to effective field use » is too slow if 
we follow the « old ways ». 
 
It is time for a change and for action : 
 
• Need to « act » the preparedness through large 
collaborations 
• Demonstration of the key industrial steps through 
prototype projects such as ZAPI 
Conclusions (3) 
www.zapi-imi.eu 
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Thank you for your attention 
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20 Partners in ZAPI consortium 
EFPIA partners : 
• Merial    EFPIA coordinator 
• Boehringer Ingelheim Animal Health EFPIA partner 
• AstraZeneca / Medimmune  EFPIA partner 
    
Public consortium partners: 
 Erasmus Medical Center NL  Univ. Klin. Bonn DE 
 CVI Lelystad NL   Viroclinics Biosciences NL 
 Utrecht University NL  CSIC Madrid SP 
 Leyden University NL  IRTA-CReSA SP 
 FLI Riems  DE   TiHo Hannover DE 
 Institut Pasteur FR   Aix-Marseille Univ. FR 
 IABS-EU FR / BE 
 
SMEs Dyadic NDL Wageningen NL  Artemis NL  
 Harbour Antibodies Rotterdam NL Finovatis FR 
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